Risk of Non-Melanoma Cancers in First-Degree Relatives of CDKN2A Mutation Carriers-Reference-Cited by-同舟云学术

Risk of Non-Melanoma Cancers in First-Degree Relatives of CDKN2A Mutation Carriers

Published:2012-05-25 Issue:12 Volume:104 Page:953-956
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Mukherjee Bhramar,DeLancey John Oliver,Raskin Leon,Everett Jessica,Jeter Joanne,Begg Colin B.,Orlow Irene,Berwick Marianne,Armstrong Bruce K.,Kricker Anne,Marrett Loraine D.,Millikan Robert C.,Culver Hoda Anton,Rosso Stefano,Zanetti Roberto,Kanetsky Peter A.,From Lynn,Gruber Stephen B.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/104/12/953/17311635/djs221.pdf

Reference27 articles.

1. Germline p16 mutations in familial melanoma;Hussussian;Nat Genet.,1994

2. CDKN2A common variant and multi-organ cancer risk—a population-based study;Debniak;Int J Cancer.,2006

3. Extending the p16-Leiden tumour spectrum by respiratory tract tumours;Oldenburg;J Med Genet.,2004

4. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations;Goldstein;N Engl J Med.,1995

5. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994;Hille;J Invest Dermatol.,1998

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding familial risk of pancreatic ductal adenocarcinoma;Familial Cancer;2024-04-12

2. Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment;International Journal of Molecular Sciences;2023-09-21

3. Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia;Tumors of the Pancreas;2023-03

4. Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities;Cancers;2022-05-21

5. Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants;Frontiers in Oncology;2022-03-16